|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2011-4-4
|
|
pubmed:abstractText |
Tumor-specific replication-selective oncolytic virotherapy is a promising antitumor therapy for induction of cell death in tumor cells but not of normal cells. We previously developed an oncolytic adenovirus, OBP-301, that kills human epithelial malignant cells in a telomerase-dependent manner. Recent evidence suggests that nonepithelial malignant cells, which have low telomerase activity, maintain telomere length through alternative lengthening of telomeres (ALT). However, it remains unclear whether OBP-301 is cytopathic for nonepithelial malignant cells. Here, we evaluated the antitumor effect of OBP-301 on human bone and soft tissue sarcoma cells.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:FujiwaraToshiyoshiT,
pubmed-author:HashimotoYuuriY,
pubmed-author:HauriHH,
pubmed-author:KagawaShunsukeS,
pubmed-author:KunisadaToshiyukiT,
pubmed-author:MorimotoYukiY,
pubmed-author:OzakiToshifumiT,
pubmed-author:SasakiTsuyoshiT,
pubmed-author:TazawaHiroshiH,
pubmed-author:UnoFutoshiF,
pubmed-author:UrataYasuoY,
pubmed-author:YanoShuyaS,
pubmed-author:YoshidaAkiA,
pubmed-author:YoshidaRyosukeR
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1828-38
|
|
pubmed:meshHeading |
pubmed-meshheading:21325287-Adenoviridae,
pubmed-meshheading:21325287-Animals,
pubmed-meshheading:21325287-Bone Neoplasms,
pubmed-meshheading:21325287-Cell Line, Tumor,
pubmed-meshheading:21325287-Cell Survival,
pubmed-meshheading:21325287-Cytopathogenic Effect, Viral,
pubmed-meshheading:21325287-Female,
pubmed-meshheading:21325287-Humans,
pubmed-meshheading:21325287-Mice,
pubmed-meshheading:21325287-Mice, Nude,
pubmed-meshheading:21325287-Neoplasm Transplantation,
pubmed-meshheading:21325287-Oncolytic Virotherapy,
pubmed-meshheading:21325287-Receptors, Virus,
pubmed-meshheading:21325287-Sarcoma,
pubmed-meshheading:21325287-Soft Tissue Neoplasms,
pubmed-meshheading:21325287-Telomerase,
pubmed-meshheading:21325287-Transcription, Genetic,
pubmed-meshheading:21325287-Transplantation, Heterologous,
pubmed-meshheading:21325287-Tumor Burden,
pubmed-meshheading:21325287-Up-Regulation,
pubmed-meshheading:21325287-Virus Replication
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Preclinical evaluation of telomerase-specific oncolytic virotherapy for human bone and soft tissue sarcomas.
|
|
pubmed:affiliation |
Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Kita-ku, Okayama, Japan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
